Armistice Capital, LLC 13D and 13G filings for Enlivex Therapeutics Ltd.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-08-14 9:03 pm Purchase | 2025-06-30 | 13G | Enlivex Therapeutics Ltd. ENLV | Armistice Capital, LLC | 209,340 4.990% | 209,340 (New Position) | Filing |
| 2025-05-15 3:27 pm Sale | 2025-03-31 | 13G | Enlivex Therapeutics Ltd. ENLV | Armistice Capital, LLC | 1,781,931 7.530% | -426,069 (-19.30%) | Filing |
| 2025-02-14 5:43 pm Purchase | 2024-12-31 | 13G | Enlivex Therapeutics Ltd. ENLV | Armistice Capital, LLC | 2,208,000 9.750% | 32,116 (+1.48%) | Filing |
| 2024-11-14 3:29 pm Purchase | 2024-09-30 | 13G | Enlivex Therapeutics Ltd. ENLV | Armistice Capital, LLC | 2,175,884 9.990% | 2,175,884 (New Position) | Filing |